Prostate Cancer
Prostate Cancer
Zachary BessetteLocalized Prostate Cancer | December 5, 2022
18F-sodium fluoride positron emission tomography-computed tomography may better detect skeletal metastases in patients
Read More
Emily MenendezmCRPC | December 5, 2022
Further study is needed to determine if certain biomarkers can aid in determining effectiveness and safety.
Leah LawrenceProstate Cancer | November 29, 2022
Two studies emphasize the need for ethnically diverse prostate cancer genomics data and accessible genetic testing.
Leah LawrenceProstate Cancer | November 29, 2022
An analysis of enrollment incidence ratios revealed that Black & Hispanic patients were both underrepresented in U.S. trials.
Leah LawrenceProstate Cancer | November 29, 2022
There was an improvement in freedom from PSA progression among patients assigned to enzalutamide compared with placebo.
Emily MenendezRLT-PSMA | November 29, 2022
The effectiveness of PSMA PET was compared with conventional imaging & liver biopsy, and a radiomic model was also evaluated.
Emily MenendezRLT-PSMA | November 29, 2022
Between [225Ac]Ac-SibuDAB and [225Ac]Ac-PSMA-617, one treatment was more effective against PSMA-positive tumor xenografts.
Emily MenendezRLT-PSMA | November 29, 2022
68Ga-PSMA PET/CT may play a role in the detection of local or systemic disease in patients with prostate cancer.
Akhil Abraham Saji, MDJournal | November 22, 2022
The history of robot-assisted laparoscopic & open radical prostatectomies are discussed with their outcomes and future uses.
Catherine H. Marshall, MD, MPHJournal | November 22, 2022
Dr. Catherine H. Marshall is interviewed on the use and future of chemotherapy for the treatment of advanced prostate cancer.
A polygenic hazard score (PHS290) is able to stratify US veterans of diverse ancestry for lifetime risk of prostate cancer.
A study assessed the link between benign prostatic hyperplasia (BPH) and prostate cancer (PCa).
A corrected genetic risk score (GRS) based on non-European racial/ethnic populations is more appropriate for genetic testing.
Genetic testing rates are low for prostate cancer.
Emily MenendezmCRPC | November 17, 2022
Olaparib is the first and only PARP inhibitor to be approved for use in the EU for the treatment of prostate cancer patients.
Daniel Tennenbaum, MDPhenotypic Precision Medicine in Advanced Prostate Cancer | November 15, 2022
Andrew Armstrong, MD ScM FACP, is interviewed by Daniel Tennenbaum, MD on new research in phenotypic precision medicine.
Leah LawrenceProstate Cancer | November 15, 2022
Using the MRI and combined biopsy strategy resulted in an incremental cost-effectiveness ratio of $53,736.
Leah LawrenceRLT-PSMA | November 15, 2022
Improvements in PET–CT and repeat issues with ⁹⁹mTc supply have sparked interest in ¹⁸F-NaF PET–CT to detect bone ...
Emily MenendezRLT-PSMA | November 14, 2022
The phase 2 TheraP trial found that higher gallium-68–labeled PSMA-11-PET SUVmean had a higher chance of PSA response.
Emily MenendezRLT-PSMA | November 14, 2022
A radiotracer for prostate cancer biopsy punching can be applied to targeted biopsy to reduce the need for saturated biopsy.